224 related articles for article (PubMed ID: 30612951)
1. What Makes a Kinase Promiscuous for Inhibitors?
Hanson SM; Georghiou G; Thakur MK; Miller WT; Rest JS; Chodera JD; Seeliger MA
Cell Chem Biol; 2019 Mar; 26(3):390-399.e5. PubMed ID: 30612951
[TBL] [Abstract][Full Text] [Related]
2. Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors.
Canning P; Tan L; Chu K; Lee SW; Gray NS; Bullock AN
J Mol Biol; 2014 Jun; 426(13):2457-70. PubMed ID: 24768818
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of novel dasatinib analogues as potent DDR1 and DDR2 kinase inhibitors.
Liu L; Hussain M; Luo J; Duan A; Chen C; Tu Z; Zhang J
Chem Biol Drug Des; 2017 Mar; 89(3):420-427. PubMed ID: 27589335
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.
Day E; Waters B; Spiegel K; Alnadaf T; Manley PW; Buchdunger E; Walker C; Jarai G
Eur J Pharmacol; 2008 Dec; 599(1-3):44-53. PubMed ID: 18938156
[TBL] [Abstract][Full Text] [Related]
5. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel discoidin domain receptor 1 (DDR1) inhibitors using E-pharmacophore modeling, structure-based virtual screening, molecular dynamics simulation and MM-GBSA approaches.
Nada H; Lee K; Gotina L; Pae AN; Elkamhawy A
Comput Biol Med; 2022 Mar; 142():105217. PubMed ID: 35032738
[TBL] [Abstract][Full Text] [Related]
7. Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.
Kwarcinski FE; Brandvold KR; Phadke S; Beleh OM; Johnson TK; Meagher JL; Seeliger MA; Stuckey JA; Soellner MB
ACS Chem Biol; 2016 May; 11(5):1296-304. PubMed ID: 26895387
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 4-amino-1H-pyrazolo[3,4-d]pyrimidin derivatives as novel discoidin domain receptor 1 (DDR1) inhibitors.
Dong R; Zhou X; Wang M; Li W; Zhang JY; Zheng X; Tang KX; Sun LP
Bioorg Med Chem; 2021 Jan; 29():115876. PubMed ID: 33246255
[TBL] [Abstract][Full Text] [Related]
9. Structure of the ABL2/ARG kinase in complex with dasatinib.
Ha BH; Simpson MA; Koleske AJ; Boggon TJ
Acta Crystallogr F Struct Biol Commun; 2015 Apr; 71(Pt 4):443-8. PubMed ID: 25849507
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel inhibitors of DDR1 against idiopathic pulmonary fibrosis by integrative transcriptome meta-analysis, computational and experimental screening.
Chen C; Deng J; Yu X; Wu F; Men K; Yang Q; Zhu Y; Liu X; Jiang Q
Mol Biosyst; 2016 Apr; 12(5):1540-51. PubMed ID: 26956955
[TBL] [Abstract][Full Text] [Related]
11. The Journey of DDR1 and DDR2 Kinase Inhibitors as Rising Stars in the Fight Against Cancer.
Elkamhawy A; Lu Q; Nada H; Woo J; Quan G; Lee K
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207360
[TBL] [Abstract][Full Text] [Related]
12. A patent review of discoidin domain receptor 1 (DDR1) modulators (2014-present).
Guo J; Zhang Z; Ding K
Expert Opin Ther Pat; 2020 May; 30(5):341-350. PubMed ID: 32077340
[No Abstract] [Full Text] [Related]
13. Perspective on computational and structural aspects of kinase discovery from IPK2014.
Martin E; Knapp S; Engh RA; Moebitz H; Varin T; Roux B; Meiler J; Berdini V; Baumann A; Vieth M
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1595-604. PubMed ID: 25861861
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor.
Kim HG; Tan L; Weisberg EL; Liu F; Canning P; Choi HG; Ezell SA; Wu H; Zhao Z; Wang J; Mandinova A; Griffin JD; Bullock AN; Liu Q; Lee SW; Gray NS
ACS Chem Biol; 2013 Oct; 8(10):2145-50. PubMed ID: 23899692
[TBL] [Abstract][Full Text] [Related]
15. Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors.
Wang Z; Bian H; Bartual SG; Du W; Luo J; Zhao H; Zhang S; Mo C; Zhou Y; Xu Y; Tu Z; Ren X; Lu X; Brekken RA; Yao L; Bullock AN; Su J; Ding K
J Med Chem; 2016 Jun; 59(12):5911-6. PubMed ID: 27219676
[TBL] [Abstract][Full Text] [Related]
16. Design and Synthesis of DDR1 Inhibitors with a Desired Pharmacophore Using Deep Generative Models.
Yoshimori A; Asawa Y; Kawasaki E; Tasaka T; Matsuda S; Sekikawa T; Tanabe S; Neya M; Natsugari H; Kanai C
ChemMedChem; 2021 Mar; 16(6):955-958. PubMed ID: 33289306
[TBL] [Abstract][Full Text] [Related]
17. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src.
Hari SB; Perera BG; Ranjitkar P; Seeliger MA; Maly DJ
ACS Chem Biol; 2013 Dec; 8(12):2734-43. PubMed ID: 24106839
[TBL] [Abstract][Full Text] [Related]
18. DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors.
Ung PM; Schlessinger A
ACS Chem Biol; 2015 Jan; 10(1):269-78. PubMed ID: 25420233
[TBL] [Abstract][Full Text] [Related]
19. Type II Inhibitors Targeting CDK2.
Alexander LT; Möbitz H; Drueckes P; Savitsky P; Fedorov O; Elkins JM; Deane CM; Cowan-Jacob SW; Knapp S
ACS Chem Biol; 2015 Sep; 10(9):2116-25. PubMed ID: 26158339
[TBL] [Abstract][Full Text] [Related]
20. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
Elife; 2020 Nov; 9():. PubMed ID: 33226337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
